AstraZeneca stock gains as analysts see upside ahead of next earnings
Published on 09/11/2026 at 15:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock (ISIN US6549022043) finished the latest session at around 11,758.0 pence on the London Stock Exchange on September 10, 2026, up 0.93 percent on the day and implying a market capitalization near 247.69 billion USD as of that close. According to MarketBeat, the shares correspond to a New York closing price of 159.71 dollars on September 10, 2026, leaving room versus a consensus analyst target of 206.67 dollars.
Analysts see upside but remain divided
According to MarketBeat, AstraZeneca carries a consensus Moderate Buy rating with an average price target of 206.67 dollars, implying about 29.4 percent upside from the recent New York price of 159.71 dollars as of September 10, 2026. The overview cites 14 buy ratings, 2 hold ratings and 1 sell rating, underlining that while the majority of analysts are positive, a minority remains cautious about the valuation. The same data show that AstraZeneca shares started 2026 at 183.14 dollars and have since fallen by 12.8 percent to 159.71 dollars, so the stock is trading meaningfully below its year opening level even as the long term pipeline remains in focus.
Per Zacks on September 9, 2026, AstraZeneca is expected to report its next quarterly earnings on November 5, 2026, with a consensus EPS estimate of 2.17 dollars for the quarter ending in September 2026. Zacks notes that this would represent a year over year decrease of 8.82 percent compared with the same quarter a year earlier, highlighting that the bar for earnings growth is relatively high. For the most recently reported quarter before this upcoming release, AstraZeneca delivered EPS of 2.63 dollars versus a Zacks consensus of 2.50 dollars, beating expectations by 5.20 percent and showing that the company has recently outperformed analyst forecasts.
Earnings trends and pipeline developments
The latest Zacks data indicate that AstraZeneca is forecast to miss its upcoming quarterly consensus EPS of 2.17 dollars by about 9.91 percent, underscoring that some analysts see pressure on profitability even as revenue growth continues in key therapy areas. According to Zacks, the prior quarter EPS beat of 0.13 dollars versus consensus (2.63 dollars reported versus 2.50 dollars expected) gives the company a recent track record of positive surprises that investors will weigh against the softer outlook for the September 2026 quarter. This quantified pattern, with one quarter beating expectations by 5.20 percent and the next potentially down 8.82 percent year on year if estimates hold, illustrates the push and pull between maturing products and the ramp up of newer launches.
In the oncology franchise, a combination therapy developed by AstraZeneca and Amgen recently showed a survival benefit in a lung cancer study, adding a qualitative pillar to the growth story. As Yahoo Finance reports on September 10, 2026, the Amgen and AstraZeneca drug combination delivered a survival benefit in a trial for lung cancer patients, with AstraZeneca currently holding a Zacks Rank of 4, equivalent to a Sell recommendation, reflecting near term caution despite the positive trial news. For investors, this combination of encouraging pipeline data and a cautious short term ranking means that the upcoming November 2026 earnings report may serve as a key checkpoint on how quickly such advances translate into revenue and margin trends.
Stock level and trading metrics
On the primary London listing, historical data compiled by Investing.com show that AstraZeneca stock closed at 11,758.0 pence on September 10, 2026, gaining 108.0 pence or 0.93 percent from the prior close, with an intraday range between 11,552.2 pence and 11,800.0 pence and reported volume of about 1.70 million shares. A London price around 11,758.0 pence corresponds to roughly 159.71 dollars on the New York Stock Exchange as cited by MarketBeat for the same day, placing the shares noticeably below their 52 week high of 212.71 dollars and above the 52 week low of 145.79 dollars given in the same overview, so the stock is trading in the middle to upper part of its yearly range.
According to MarketBeat, AstraZeneca shares carry a price to earnings ratio of 23.87 based on recent earnings and offer a dividend yield of 2.72 percent as of the New York close on September 10, 2026, with a reported market capitalization of 247.69 billion dollars. The same data indicate that the stock has declined 12.8 percent year to date from 183.14 dollars to 159.71 dollars, while the consensus price target of 206.67 dollars suggests potential upside of about 29.4 percent if the company can execute on its pipeline and earnings guidance.
AstraZeneca stock and investor perspective
From an investor perspective, AstraZeneca stock is currently balancing mixed signals: a Moderate Buy analyst consensus and a 29.4 percent implied upside from the 159.71 dollar New York price as of September 10, 2026, alongside a Zacks Rank 4 Sell designation driven by an expected 8.82 percent year over year decline in EPS for the September 2026 quarter. With the London closing price of 11,758.0 pence on September 10, 2026, sitting comfortably between the 52 week low of 145.79 dollars and the high of 212.71 dollars on the New York line, the shares appear neither distressed nor at peak valuation, and the next earnings release on November 5, 2026 will be watched closely to see whether recent trial successes and the existing product portfolio can re accelerate growth.
Key data on AstraZeneca stock
- Company: AstraZeneca PLC
- ISIN: US6549022043
- Ticker: AZN
- Trading venue: London Stock Exchange (primary listing), NYSE ADR in USD
- Price (as of September 10, 2026): 11,758.0 pence GBP
- Market capitalization: 247.69 billion USD (as of September 10, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals and Biotechnology
- Index membership: FTSE 100
- Next earnings date: November 5, 2026
